14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan. // The Lancet. – URL: https://www.sciencedirect.com/science/article/pii/S0140673626017824?dgcid=rss_sd_all
14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan. The Lancet. https://www.sciencedirect.com/science/article/pii/S0140673626017824?dgcid=rss_sd_all
“14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.” The Lancet.
@article{article68256,
title = {14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan},
journal = {The Lancet},
url = {https://www.sciencedirect.com/science/article/pii/S0140673626017824?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...